Zyme Communications
@zymecommunications.bsky.social
Specialist communications for life sciences
Pinned
A lovely way to start the year – Zyme is named #1 Marketing Agency by @businessweekly.bsky.social, with reference to the quality of our work, our global expansion, and recruitment. Congratulations to all the agencies listed in the top 10, and thank you Tony Quested and of course our brilliant team!
Bio-Rad today announce it has received validation from AOAC International for its EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits for the detection of Listeria spp. and Listeria monocytogenes in food products and environmental samples.
Read the full press release: shorturl.at/yiYT3
Read the full press release: shorturl.at/yiYT3
February 6, 2026 at 10:19 AM
Bio-Rad today announce it has received validation from AOAC International for its EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits for the detection of Listeria spp. and Listeria monocytogenes in food products and environmental samples.
Read the full press release: shorturl.at/yiYT3
Read the full press release: shorturl.at/yiYT3
SynGenSys today launched its Liver.SET™ library of liver-specific synthetic promoters – a range of compact, patentable synthetic promoters designed for liver-targeted gene expression for in vivo gene therapies.
Read the full press release here: tinyurl.com/mrx6uhby
Read the full press release here: tinyurl.com/mrx6uhby
February 5, 2026 at 9:23 AM
SynGenSys today launched its Liver.SET™ library of liver-specific synthetic promoters – a range of compact, patentable synthetic promoters designed for liver-targeted gene expression for in vivo gene therapies.
Read the full press release here: tinyurl.com/mrx6uhby
Read the full press release here: tinyurl.com/mrx6uhby
Vortex Biosciences has officially opened its new state-of-the-art laboratory at Manchester Science Park. The expansion enhances the company’s R&D and commercial delivery capacity, solidifying Vortex’s position as a leader in liquid biopsy technologies for precision oncology:https://shorturl.at/GMohL
January 27, 2026 at 3:04 PM
Vortex Biosciences has officially opened its new state-of-the-art laboratory at Manchester Science Park. The expansion enhances the company’s R&D and commercial delivery capacity, solidifying Vortex’s position as a leader in liquid biopsy technologies for precision oncology:https://shorturl.at/GMohL
iXCells Biotechnologies and Rosebud Biosciences have announced a partnership to advance organoid-based models for rare diseases.
Together, they are developing a personalized human-based approach for predicting drug safety and tissue-specific responses.
Read the press release: bit.ly/4k1tDPd
Together, they are developing a personalized human-based approach for predicting drug safety and tissue-specific responses.
Read the press release: bit.ly/4k1tDPd
January 27, 2026 at 2:25 PM
iXCells Biotechnologies and Rosebud Biosciences have announced a partnership to advance organoid-based models for rare diseases.
Together, they are developing a personalized human-based approach for predicting drug safety and tissue-specific responses.
Read the press release: bit.ly/4k1tDPd
Together, they are developing a personalized human-based approach for predicting drug safety and tissue-specific responses.
Read the press release: bit.ly/4k1tDPd
@proimmune.bsky.social has introduced Mastering Immunity 2026 – Shanghai, its symposium providing guidance to help drug developers manage immunogenicity risk.
Speakers include leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities: www.proimmune.com/mastering-im...
Speakers include leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities: www.proimmune.com/mastering-im...
January 21, 2026 at 8:52 AM
@proimmune.bsky.social has introduced Mastering Immunity 2026 – Shanghai, its symposium providing guidance to help drug developers manage immunogenicity risk.
Speakers include leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities: www.proimmune.com/mastering-im...
Speakers include leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities: www.proimmune.com/mastering-im...
@enhancedgenomics.bsky.social announced the appointment of Dr Katerina Leftheris to its Board of Directors to support expansion of the Company’s therapeutics pipeline for complex and common genetic diseases.
Read more: tinyurl.com/2bb2dz75
Read more: tinyurl.com/2bb2dz75
January 15, 2026 at 1:28 PM
@enhancedgenomics.bsky.social announced the appointment of Dr Katerina Leftheris to its Board of Directors to support expansion of the Company’s therapeutics pipeline for complex and common genetic diseases.
Read more: tinyurl.com/2bb2dz75
Read more: tinyurl.com/2bb2dz75
@sptlabtech.bsky.social & Twist Bioscience collaborate to automate Twist's next-generation sequencing (NGS) library preparation on SPT's firefly liquid handling platform, enabling higher throughput & reproducibility in library preparation - accessible directly via the firefly cloud: bit.ly/45dcfRn
January 14, 2026 at 9:21 AM
@sptlabtech.bsky.social & Twist Bioscience collaborate to automate Twist's next-generation sequencing (NGS) library preparation on SPT's firefly liquid handling platform, enabling higher throughput & reproducibility in library preparation - accessible directly via the firefly cloud: bit.ly/45dcfRn
@axolbio.bsky.social today announce it has secured $2.8 million in funding to advance US expansion and product development. The investment was led by US life sciences specialist BroadOak Capital Partners, accompanied by the Rosalin Foundation, the company's founding investor.
bit.ly/4567FV4
bit.ly/4567FV4
January 13, 2026 at 4:27 PM
@axolbio.bsky.social today announce it has secured $2.8 million in funding to advance US expansion and product development. The investment was led by US life sciences specialist BroadOak Capital Partners, accompanied by the Rosalin Foundation, the company's founding investor.
bit.ly/4567FV4
bit.ly/4567FV4
OutSee completes oversubscribed £2.5M seed funding round and establishes strategic partnership with o2h discovery for lead drug target candidate.
Read the full press release: bit.ly/4pA7gRO
Read the full press release: bit.ly/4pA7gRO
January 13, 2026 at 12:19 PM
OutSee completes oversubscribed £2.5M seed funding round and establishes strategic partnership with o2h discovery for lead drug target candidate.
Read the full press release: bit.ly/4pA7gRO
Read the full press release: bit.ly/4pA7gRO
Today Optibrium announced the appointment of Dr Nathan Brown as Director of Science. In this new role, Nathan will lead the Research and Application Science teams to drive development of new AI-based discovery methods.
bit.ly/3NGeFBQ
bit.ly/3NGeFBQ
January 13, 2026 at 11:12 AM
Today Optibrium announced the appointment of Dr Nathan Brown as Director of Science. In this new role, Nathan will lead the Research and Application Science teams to drive development of new AI-based discovery methods.
bit.ly/3NGeFBQ
bit.ly/3NGeFBQ
Today Nuclera has announced an extension to its Series C funding to $87M. The additional $12M will be used to integrate end-to-end antibody expression, purification and binding validation into the Company’s eProtein Discovery System.
bit.ly/45SicmS
bit.ly/45SicmS
January 13, 2026 at 10:10 AM
Today Nuclera has announced an extension to its Series C funding to $87M. The additional $12M will be used to integrate end-to-end antibody expression, purification and binding validation into the Company’s eProtein Discovery System.
bit.ly/45SicmS
bit.ly/45SicmS
iXCells Biotechnologies has announced the appointment of Steve Smith as CEO, enabling expansions of its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services.
Read the full press release: ixcellsbiotech.com/iXCells-Biot...
Read the full press release: ixcellsbiotech.com/iXCells-Biot...
January 12, 2026 at 2:19 PM
iXCells Biotechnologies has announced the appointment of Steve Smith as CEO, enabling expansions of its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services.
Read the full press release: ixcellsbiotech.com/iXCells-Biot...
Read the full press release: ixcellsbiotech.com/iXCells-Biot...
FairJourney Bio today announced the launch of cryo-EM services, supported through the Company's advanced laboratories in San Diego, CA.
The new offering provides high-resolution structural insights to support antibody discovery and biologic design.
Read more here: bit.ly/453JkPB
The new offering provides high-resolution structural insights to support antibody discovery and biologic design.
Read more here: bit.ly/453JkPB
January 12, 2026 at 1:47 PM
FairJourney Bio today announced the launch of cryo-EM services, supported through the Company's advanced laboratories in San Diego, CA.
The new offering provides high-resolution structural insights to support antibody discovery and biologic design.
Read more here: bit.ly/453JkPB
The new offering provides high-resolution structural insights to support antibody discovery and biologic design.
Read more here: bit.ly/453JkPB
Reposted by Zyme Communications
Today Qureight announced the appointment of Rebecca Simmons as Chief Operating Officer.
Bringing over 20 years of operational leadership experience, Rebecca will lead sustainable growth initiatives to support the Company as it scales its global operations.
bit.ly/4jE2wte
Bringing over 20 years of operational leadership experience, Rebecca will lead sustainable growth initiatives to support the Company as it scales its global operations.
bit.ly/4jE2wte
January 12, 2026 at 9:23 AM
Today Qureight announced the appointment of Rebecca Simmons as Chief Operating Officer.
Bringing over 20 years of operational leadership experience, Rebecca will lead sustainable growth initiatives to support the Company as it scales its global operations.
bit.ly/4jE2wte
Bringing over 20 years of operational leadership experience, Rebecca will lead sustainable growth initiatives to support the Company as it scales its global operations.
bit.ly/4jE2wte
For those heading out to JPM, FairJourney Bio has announced that its CEO, Dr. Werner Lanthaler, will present at the conference, where he will showcase the Company’s antibody discovery and development solutions.
Find out more here: bit.ly/49e07lz
Find out more here: bit.ly/49e07lz
January 8, 2026 at 10:39 AM
For those heading out to JPM, FairJourney Bio has announced that its CEO, Dr. Werner Lanthaler, will present at the conference, where he will showcase the Company’s antibody discovery and development solutions.
Find out more here: bit.ly/49e07lz
Find out more here: bit.ly/49e07lz
Today Nuclera announced the first installations of eProtein Discovery in Asia, with systems now operational at National Taiwan University and National Cheng Kung University supporting the Company’s global expansion.
eprote.in/1CDmvHqq
eprote.in/1CDmvHqq
January 7, 2026 at 10:38 AM
Today Nuclera announced the first installations of eProtein Discovery in Asia, with systems now operational at National Taiwan University and National Cheng Kung University supporting the Company’s global expansion.
eprote.in/1CDmvHqq
eprote.in/1CDmvHqq
Qureight has announced the appointment of Dr Steven Bishop, previously Chief Data Officer, as Chief Medical Officer (CMO), reflecting the Company’s continued growth and commercial success in advancing clinical studies.
bit.ly/4qbFwo3
bit.ly/4qbFwo3
January 7, 2026 at 9:40 AM
Qureight has announced the appointment of Dr Steven Bishop, previously Chief Data Officer, as Chief Medical Officer (CMO), reflecting the Company’s continued growth and commercial success in advancing clinical studies.
bit.ly/4qbFwo3
bit.ly/4qbFwo3
Today Fujifilm Biosciences has announced that its name change from FUJIFILM Irvine Scientific, announced in June 2025, is now official, reflecting the range of support the Company offers to researchers across the life science community.
bit.ly/3YWw7o5
bit.ly/3YWw7o5
January 5, 2026 at 2:51 PM
Today Fujifilm Biosciences has announced that its name change from FUJIFILM Irvine Scientific, announced in June 2025, is now official, reflecting the range of support the Company offers to researchers across the life science community.
bit.ly/3YWw7o5
bit.ly/3YWw7o5
Today FUJIFILM Biosciences has announced a strategic alliance with CHITOSE, combining CHITOSE’s expertise in cell line development with FUJIFILM Biosciences’ advanced culture media development, to drive global innovation and biopharmaceutical manufacturing.
More: bit.ly/495M00j
More: bit.ly/495M00j
December 18, 2025 at 2:14 PM
Today FUJIFILM Biosciences has announced a strategic alliance with CHITOSE, combining CHITOSE’s expertise in cell line development with FUJIFILM Biosciences’ advanced culture media development, to drive global innovation and biopharmaceutical manufacturing.
More: bit.ly/495M00j
More: bit.ly/495M00j
Atelerix today announced a partnership with Cherry Biotech, bringing together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in the preclinical research and biotech sectors.
Read more: rb.gy/ver8ru
Read more: rb.gy/ver8ru
December 15, 2025 at 9:57 AM
Atelerix today announced a partnership with Cherry Biotech, bringing together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in the preclinical research and biotech sectors.
Read more: rb.gy/ver8ru
Read more: rb.gy/ver8ru
EpilepsyGTx has raised $33 million in Series A financing to advance its lead gene therapy programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company: www.epilepsygtx.com/news/epileps...
December 10, 2025 at 10:20 AM
EpilepsyGTx has raised $33 million in Series A financing to advance its lead gene therapy programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company: www.epilepsygtx.com/news/epileps...
Enterprise Therapeutics has published results of its Phase 1 study of ETD001 in the Journal of Cystic Fibrosis, demonstrating that ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic.
bit.ly/44JW11K
bit.ly/44JW11K
December 9, 2025 at 11:55 AM
Enterprise Therapeutics has published results of its Phase 1 study of ETD001 in the Journal of Cystic Fibrosis, demonstrating that ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic.
bit.ly/44JW11K
bit.ly/44JW11K
VALANX Biotech today announced the formation of its Board of Directors, bringing together industry leaders to support the company's strategic direction as VALANX advances from a research-stage organisation into clinical development and technology commercialisation.
Read more: bit.ly/3Y2voS9
Read more: bit.ly/3Y2voS9
December 9, 2025 at 10:41 AM
VALANX Biotech today announced the formation of its Board of Directors, bringing together industry leaders to support the company's strategic direction as VALANX advances from a research-stage organisation into clinical development and technology commercialisation.
Read more: bit.ly/3Y2voS9
Read more: bit.ly/3Y2voS9
This morning, Lab Thread announced the beta release of its flagship platform, a unified lab software designed to simplify and streamline collaboration across biological research.
Read the full press release here: bit.ly/48DZXlH
Read the full press release here: bit.ly/48DZXlH
December 8, 2025 at 9:08 AM
This morning, Lab Thread announced the beta release of its flagship platform, a unified lab software designed to simplify and streamline collaboration across biological research.
Read the full press release here: bit.ly/48DZXlH
Read the full press release here: bit.ly/48DZXlH